Trevi's Q4 Net Loss Narrows; Plans 2 Pivotal Phase 3 Trials For Haduvio In Q2 And H2 2026

Trevi Therapeutics reported fourth-quarter and full-year 2025 results showing a narrower loss and provided updates on trials of its lead investigational therapy, Haduvio. The article excerpt does not quantify the loss or detail trial outcomes, indicating limited positive operational progress but continued clinical risk. The release is mildly positive for the equity but material stock moves will depend on the specifics of the financials and upcoming clinical readouts.

Analysis

Trevi Therapeutics reported fourth-quarter and full-year 2025 results showing a narrower loss and provided updates on trials of its lead investigational therapy, Haduvio. The article excerpt does not quantify the loss or detail trial outcomes, indicating limited positive operational progress but continued clinical risk. The release is mildly positive for the equity but material stock moves will depend on the specifics of the financials and upcoming clinical readouts.